The role of cytokines in the pathogenesis of systemic lupus erythematosus from bench to bedside

被引:78
作者
Yap, Desmond Yat Hin [1 ]
Lai, Kar Neng [1 ,2 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Nephrol, Hong Kong, Hong Kong, Peoples R China
[2] Hong Kong Sanat & Hosp, Nephrol Ctr, Hong Kong, Hong Kong, Peoples R China
关键词
BLys; IFN; IL-6; IL-17; IL-18; TNF; systemic lupus erythematosus; TUMOR-NECROSIS-FACTOR; B-LYMPHOCYTE STIMULATOR; PLASMACYTOID DENDRITIC CELLS; INTERFERON-ALPHA ACTIVITY; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; MRL-LPR MICE; DISEASE-ACTIVITY; TNF-ALPHA; I INTERFERON;
D O I
10.1111/nep.12047
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The pathogenesis of systemic lupus erythematosus (SLE) entails a complex interaction between the different arms of the immune system. While autoantibodies production and immune complex deposition are cornered as hallmark features of SLE, there is growing evidence to propose the pathogenic role of cytokines in this disease. Examples of these cytokines include BLys, interleukin-6, interleukin-17, interleukin-18, type I interferons and tumour necrosis factor alpha. These cytokines all assume pivotal functions to orchestrate the differentiation, maturation and activation of various cell types, which would mediate local inflammatory process and tissue injury. The knowledge on these cytokines not only fosters our understanding of the disease, but also provides insights in devising biomarkers and targeted therapies. In this review, we focus on cytokines which have substantial pathogenic significance and also highlight the possible clinical applications of these cytokines.
引用
收藏
页码:243 / 255
页数:13
相关论文
共 150 条
[1]  
Agarwal S, 2008, J RHEUMATOL, V35, P515
[2]   Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J].
Aggarwal, S ;
Ghilardi, N ;
Xie, MH ;
de Sauvage, FJ ;
Gurney, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1910-1914
[3]   Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease [J].
Agrawal, Hemant ;
Jacob, Noam ;
Carreras, Esther ;
Bajana, Sandra ;
Putterman, Chaim ;
Turner, Sean ;
Neas, Barbara ;
Mathian, Alexis ;
Koss, Michael N. ;
Stohl, William ;
Kovats, Susan ;
Jacob, Chaim O. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (09) :6021-6029
[4]  
Albanesi C, 1999, J IMMUNOL, V162, P494
[5]  
Amerio P, 2002, CLIN EXP RHEUMATOL, V20, P535
[6]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[7]   Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients [J].
Aringer, Martin ;
Houssiau, Frederic ;
Gordon, Caroline ;
Graninger, Winfried B. ;
Voll, Reinhard E. ;
Rath, Eva ;
Steiner, Guenter ;
Smole, Josef S. .
RHEUMATOLOGY, 2009, 48 (11) :1451-1454
[8]   Autoimmunity and anti-TNF-α agents [J].
Atzeni, F ;
Turiel, M ;
Capsoni, F ;
Doria, A ;
Meroni, P ;
Sarzi-Puttini, P .
AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 :559-569
[9]   Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study [J].
Atzeni, F ;
Ardizzone, S ;
Sarzi-Puttini, P ;
Colombo, E ;
Maconi, G ;
De Portu, S ;
Carrabba, M ;
Porro, GB .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (05) :453-461
[10]   TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity [J].
Baccala, Roberto ;
Hoebe, Kasper ;
Kono, Dwight H. ;
Beutler, Bruce ;
Theofilopoulos, Argyrios N. .
NATURE MEDICINE, 2007, 13 (05) :543-551